The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
Launched by SHANGHAI ZHONGSHAN HOSPITAL · Jul 20, 2023
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
The CHAPERONE study is looking at how screening for a specific protein called M-protein can help identify early signs of a condition called monoclonal gammopathy in people who are closely related to patients with multiple myeloma, a type of blood cancer. This study aims to understand if screening can help find individuals who may be at risk of developing multiple myeloma in the future. By gathering information from these first-degree relatives, including parents, children, and siblings, researchers hope to learn more about what factors might lead to the progression of this disease.
To be eligible for the study, participants need to be at least 18 years old and have a close family member with a diagnosed case of multiple myeloma. It's important that participants understand the purpose of the study and agree to take part in the screening process. Those who are already diagnosed with related conditions like monoclonal gammopathy or multiple myeloma cannot participate. As a participant, you can expect to undergo screening tests and follow-up as part of the study, helping contribute valuable information that could improve understanding and treatment of this condition in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male or female over the age of 18;
- • 2. First-degree relatives (including parents, children, and biological siblings) have multiple myeloma diagnosed by the International Myeloma Working Group (IMWG) Myeloma Diagnostic Criteria;
- • 3. Understand the purpose and procedure of this trial and voluntarily participate in this screening study;
- • 4. Participants should be willing and able to follow the study follow-up plan and other protocol requirements.
- Exclusion Criteria:
- • Patients with a known diagnosis of plasma cell diseases, such as MGUS, smoldering myeloma (SMM), or multiple myeloma
About Shanghai Zhongshan Hospital
Shanghai Zhongshan Hospital is a prestigious medical institution affiliated with Fudan University, renowned for its commitment to advancing healthcare through rigorous clinical research and innovative patient care. With a focus on multidisciplinary collaboration and cutting-edge medical technologies, the hospital conducts a wide range of clinical trials aimed at improving treatment outcomes across various specialties. Its state-of-the-art facilities and highly qualified research team ensure that trials adhere to the highest ethical and scientific standards, contributing significantly to the global body of medical knowledge and enhancing patient health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Trial Officials
Peng Liu, PhD, MD
Principal Investigator
Fudan University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported